# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) with a Neutral.
Mizuho analyst Salim Syed upgrades Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Outperform and lowers the price targe...
Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and maintains $13 price target.
It plans to initiate ATA3219 Systemic Lupus Erythematosus trial in the fourth quarter, including the cohort without lymphodeple...
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(3.10) per share which missed the analyst consensus estimate ...
Goldman Sachs analyst Tommie Reerink maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Sell and lowers the price target f...
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025If Approved, Tab-cel Would Be First Approved Thera...